Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Sponsor: Xencor, Inc.
Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Official title: A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
INTERVENTIONAL
Enrollment
282
Start Date
2024-04-04
Completion Date
2028-12
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
XmAb541
Monoclonal bispecific antibody
Locations (16)
City of Hope
Duarte, California, United States
Stanford
Palo Alto, California, United States
University of California
San Francisco, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indian University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
The John Theruer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
The Ohio State University
Columbus, Ohio, United States
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
University of Virginia
Charlottesville, Virginia, United States